| Field | Specification |
|---|---|
| Target | |
| Alternative names | Suramin hexasodium salt |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C51H34N6Na6O23S6 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Suramin sodium salt, also known as Suramin hexasodium salt, is a reversible, competitive inhibitor of protein-tyrosine phosphatases (PTPases)[1]. It is a potent inhibitor of the sirtuins SirT1 (IC50 = 297 nM), SirT2 (IC50 = 1.15 μM), and SirT5 (IC50 = 22 μM)[2], and a competitive inhibitor of reverse transcriptase, with an IC50 of 5 μM against DNA topoisomerase II[3][4]. It is also a potent inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp)[5], efficiently inhibits IP5K, and acts as an antiparasitic, anti-neoplastic, and anti-angiogenic agent[6][7][8]. It is supplied as an off-white to light brown solid (C51H34N6Na6O23S6, MW 1429.17) at 99.98% purity.
Physical & Chemical Properties
| CAS Number | 129-46-4 |
|---|---|
| Molecular Formula | C51H34N6Na6O23S6 |
| Molecular Weight | 1429.17 g/mol |
| Purity | 99.98% |
| Appearance | Solid |
| Color | Off-white to light brown |
| SMILES | O=C(NC1=CC(C(NC2=CC(C(NC3=CC=C(S(=O)(O[Na])=O)C4=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C34)=O)=CC=C2C)=O)=CC=C1)NC5=CC(C(NC6=CC(C(NC7=CC=C(S(=O)(O[Na])=O)C8=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C78)=O)=CC=C6C)=O)=CC=C5 |
| Target | SIRT1, SIRT2, SIRT5 |
| Signaling Pathway | Metabolic Enzyme/Protease; Epigenetics; Cell Cycle/DNA Damage; Anti-infection; Apoptosis |
| Solubility | In Vitro: DMSO: 50 mg/mL (34.99 mM; Requires sonication and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O: 50 mg/mL (34.99 mM; Requires sonication) |
| Storage | 4°C, sealed storage, away from moisture and light. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[2]
|
SIRT1 297 nM (IC50) |
SIRT2 1.15 μM (IC50) |
SIRT5 22 μM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 50 mg/mL (34.99 mM) | requires sonication and warming and heat to 60°C; use freshly opened DMSO (absorbed moisture lowers solubility) |
| H2O | 50 mg/mL (34.99 mM) | requires sonication |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture and light; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (1.46 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.08 mg/mL (1.46 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Direct preparation of the working solution
These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.
Protocol 3
| Composition | PBS |
|---|---|
| Result | 100 mg/mL (69.97 mM); clear solution; requires sonication |
Data provided by the manufacturer.
In Vitro
Cell proliferation is inhibited by Suramin sodium salt (Suramin hexasodium salt; 50-600 μg/mL; for 24-96 hours) in a dose- and time-dependent manner, and viability in cancer cells is decreased[7]. Suramin sodium salt (300 μg/mL; for 48 hours) induces cell apoptosis and downregulates mRNA expression in HeLa cells[7]. Phosphorylated ERK1/2 is significantly suppressed by Suramin sodium salt (1 mg/mL; 1 hour)[8]. The IC50 values for HO-8910 PM and HeLa are 319 μg/mL and 476 μg/mL, respectively[7]. Viral replication in Vero E6 cells is blocked by Suramin[5].
Cell Proliferation Assay[6]
| Cell Line | HO-8910 PM ovarian and Hela cervical cancer cells |
|---|---|
| Concentration | 50, 100, 200, 300, 400, 500 and 600 μg/mL |
| Incubation Time | For 24, 48, 72 and 96 hours |
| Result | Inhibited cells proliferation in a dose-dependent and time-dependent manner. |
Apoptosis Analysis[6]
| Cell Line | HeLa cells |
|---|---|
| Concentration | 300 μg/mL |
| Incubation Time | For 48 hours |
| Result | Induced cells apoptosis. |
Western Blot Analysis[7]
| Cell Line | PA-SMCs cells |
|---|---|
| Concentration | 1 mg/mL |
| Incubation Time | For 1 hour |
| Result | Significantly suppressed the phosphorylated ERK1/2. |
In Vivo
Established pulmonary hypertension (PH) is reversed by Suramin sodium salt (Suramin hexasodium salt; 10 mg/kg; IV; given twice weekly for 3 weeks), which normalizes pulmonary artery pressure values and vessel structure[8].
| Animal Model | Adult male Wistar rats (200-225 g)[7] |
|---|---|
| Dosage | 10 mg/kg |
| Administration | IV; twice weekly for 3 weeks |
| Result | Reversed established PH, thereby normalizing the pulmonary artery pressure values and vessel structure. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function. J Hematol Oncol 2025 Apr 1;18(1):38. PMID: 40170099
Dietary-timing-induced gut microbiota diurnal oscillations modulate inflammatory rhythms in rheumatoid arthritis. Cell Metab 2024 Nov 5;36(11):2367-2382.e5. PMID: 39260371
Flavin adenine dinucleotide is an endogenous suppressor for cytosolic DNA and RNA sensors to modulate innate immunity. Immunity 2026 Jul 13:S1074-7613(26)00261-X. PMID: 42442359
Ultrasound-mediated spatial and temporal control of engineered cells in vivo. Nat Commun 2024 Aug 27;15(1):7369. PMID: 39191796
Stromal Cell-Mast Cell Communication Orchestrates Anti-Viral Immunity in the Meninges. Adv Sci (Weinh) 2025 Nov 6:e14842. PMID: 41195564
Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat Struct Mol Biol 2021 Mar;28(3):319-325. PMID: 33674802
Aberrant MCM10 SUMOylation induces genomic instability mediated by a genetic variant associated with survival of esophageal squamous cell carcinoma. Clin Transl Med 2021 Jun;11(6):e485. PMID: 34185429
Transient Receptor Potential channels, TRPV1 and TRPA1 in melanocytes synergize UV-dependent and UV-independent melanogenesis. Br J Pharmacol 2021 Dec;178(23):4646-4662. PMID: 34363226
Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate. J Med Chem 2024 Aug 8;67(15):12760-12783. PMID: 39072488
Suramin, an antiparasitic drug, stimulates adipocyte differentiation and promotes adipogenesis. Lipids Health Dis 2023 Dec 13;22(1):222. PMID: 38093311
